Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Erlotinib and sorafenib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Bevacizumab, erlotinib, and sorafenib may also stop the growth of tumor cells by blocking
blood flow to the tumor. It is not yet known whether giving bevacizumab together with
erlotinib is more effective than giving sorafenib in treating patients with liver cancer.
PURPOSE: This randomized phase II trial is studying how well giving bevacizumab together with
erlotinib works compared with sorafenib as first-line therapy in treating patients with
advanced liver cancer.